Blueprint Medicines (BPMC) Tops Q3 EPS by 17c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.62), $0.17 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance
• Retail Opportunity Investments (ROIC) Tops Q1 EPS by 2c, reaffirms guidance